Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 7;96(6):1325–1337. doi: 10.4269/ajtmh.16-0634

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The American Society of Tropical Medicine and Hygiene

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Figure 2. — Overall per dose incidence of any grade solicited injection site (A) and general (B) adverse events during the 7-day postvaccination period (total vaccinated cohort). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01_E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01_E; 1 μg + AS03_B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03_B. Error bars indicate exact 95% confidence intervals; GI = gastrointestinal; Temperature = oral temperature ≥ 37.5°C. Intensities of each AE were scored as grades 1–3, with grade 3 fever defined as an oral body temperature ≥ 39°C, grade 3 redness and swelling defined as ≥ 101-mm diameter around the injection site, and all other grade 3 AEs defined as those events preventing normal daily activity.